IN THE CLAIMS

Please **cancel** claims 12-18 and 25-51.

Please **add** the following new claims:

57. (New) An immunotoxin of claim 1, wherein said immunotoxin is a disulfide-stabilized FV ("dsFv").

58. (New) An immunotoxin of claim 57, wherein said immunotoxin is 3B3dsFv-PE38.

59. (New) A nucleic acid that encodes a single chain fusion protein, said nucleic acid comprising:

(a) a nucleic acid sequence that encodes a single-chain antibody having the binding specificity of 3B3; and

(b) a nucleic acid sequence that encodes a cytotoxin.

60. (New) A nucleic acid of claim 59, wherein said cytotoxin is selected from the group consisting of ricin, abrin, a modified diphtheria toxin, and a modified *Pseudomonas* exotoxin.

61. (New) A nucleic acid of claim 59, wherein said modified *Pseudomonas* exotoxin is selected from the group consisting of PE38, PE40, PE38KDEL, and PE38REDL.

62. (New) A nucleic acid of claim 61, wherein said modified *Pseudomonas* exotoxin is PE38.

63. (New) A nucleic acid of claim 59, wherein said antibody is selected from the group consisting of a single-chain Fv (scFv), a single-chain Fab (scFab), and a disulfide stabilized Fv (dsFv).

64. (New) A nucleic acid of claim 63, wherein said antibody is a recombinantly expressed single chain Fv.

65. (New) A nucleic acid of claim 63, wherein said antibody is a dsFv.

66. (New) A nucleic acid of claim 63, wherein said antibody is 3B3(dsFv).

67. (New) A nucleic acid of claim 59, wherein said fusion protein is 3B3dsFv-PE38 or 3B3(Fv)-PE38.

68. (New) A composition, said composition comprising:
a pharmaceutically acceptable carrier or excipient; and
an immunotoxin comprising a cytotoxin attached to an anti-gp120 antibody having the binding specificity of 3B3.

69. (New) A composition of claim 68, wherein said cytotoxin is selected from the group consisting of ricin, abrin, a modified diphtheria toxin, and a modified *Pseudomonas* exotoxin.

70. (New) A composition of claim 69, in which said modified *Pseudomonas* exotoxin is selected from the group consisting of PE38, PE40, PE38KDEL, and PE38REDL.

71. (New) A composition of claim 70, wherein said modified *Pseudomonas* exotoxin is PE38.

72. (New) A composition of claim 68, wherein said antibody is selected from the group consisting of a single-chain Fv (scFv), a single-chain Fab (scFab), and a disulfide stabilized Fv (dsFv).

73. (New) A composition of claim 72, wherein said antibody is a recombinantly expressed single-chain Fv.

74. (New) A composition of claim 73, wherein said antibody is 3B3(Fv).

75. (New) A composition of claim 72, wherein said antibody is a dsFv.

76. (New) A composition of claim 75, wherein said antibody is 3B3(dsFv).

77. (New) A composition of claim 72, wherein said immunotoxin is a fusion protein.

78. (New) A composition of claim 77, wherein said immunotoxin is 3B3(Fv)-PE38.

79. (New) A method of killing or inhibiting the growth of a cell displaying a gp120 protein or fragment thereof, said method comprising contacting said

cell with an immunotoxin comprising a cytotoxin attached to an anti-gp120 antibody having the binding specificity of 3B3.

80. (New) A method of claim 79, wherein said cytotoxin is selected from the group consisting of ricin, abrin, a modified diphtheria toxin, and a modified *Pseudomonas* exotoxin.

81. (New) A method of claim 80, wherein said modified *Pseudomonas* exotoxin is selected from the group consisting of PE38, PE40, PE38KDEL, and PE38REDL.

82. (New) A method of claim 81, wherein said modified *Pseudomonas* exotoxin is PE38.

83. (New) A method of claim 79, wherein said antibody is selected from the group consisting of a single-chain Fv (scFv), a single-chain Fab (scFab), and a disulfide stabilized Fv (dsFv).

84. (New) A method of claim 83, wherein said antibody is a recombinantly expressed single-chain Fv.

85. (New) A method of claim 83, wherein said antibody is 3B3(Fv).

86. (New) A method of claim 83, wherein said antibody is a dsFv.

87. (New) A method of claim 83, wherein said antibody is 3B3(dsFv).

88. (New) A method of claim 83, wherein said immunotoxin is a fusion protein.

89. (New) A method of claim 83, wherein said immunotoxin is 3B3(Fv)-PE38.

90. (New) A method of killing or inhibiting the growth of cells bearing gp120 protein or fragment thereof, said method comprising administering to an organism containing said cells a composition comprising:

a pharmaceutically acceptable carrier or excipient; and

an immunotoxin comprising a cytotoxin attached to an anti-gp120 antibody having the binding specificity of 3B3 and minimum affinity of 3B3.

91. (New) A method of claim 90, wherein said cytotoxin is selected from the group consisting of ricin, abrin, a modified diphtheria toxin, and a modified *Pseudomonas* exotoxin.

92. (New) A method of claim 91, wherein said modified *Pseudomonas* exotoxin is selected from the group consisting of PE38, PE40, PE38KDEL, and PE38REDL.

93. (New) A method of claim 91, wherein said modified *Pseudomonas* exotoxin is PE38.

94. (New) A method of claim 90, wherein said antibody is selected from the group consisting of a single-chain Fv (scFv), a single-chain Fab (scFab), and a disulfide stabilized Fv (dsFv).

95. (New) A method of claim 94, wherein said antibody is a recombinantly expressed single-chain Fv.

96. (New) A method of claim 94, wherein said antibody is 3B3(Fv).

97. (New) A method of claim 94, wherein said antibody is a dsFv.

98. (New) A method of claim 97, wherein said antibody is 3B3(dsFv).

99. (New) A method of claim 90, wherein said immunotoxin is a fusion protein.

100. (New) A method of claim 99, wherein said immunotoxin is 3B3(Fv)-PE38.

101. (New) A method of claim 90, further comprising administering to said organism a protease inhibitor.

102. (New) A method of claim 90, further comprising administering to said organism a reverse transcriptase inhibitor.

103. (New) A method of claim 90, further comprising administering to said organism both a protease inhibitor and a reverse transcriptase inhibitor and then withdrawing the reverse transcriptase inhibitor while maintaining protease inhibitor dosing during administration of said composition.

REMARKS

I. Status of the Claims

Following entry of the amendments herein, claims 1-11, 19-24, and 52-102 are pending, with claims 12-18 and 25-51 being cancelled herein.